Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helio S Sader

Showing results (381-390 of 420) with videos related to

Pageof 42
Sort By:
Journal of Chemotherapy (Florence, Italy)|November 24, 2012
ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countriesRobert K Flamm, David J Farrell, Rodrigo E Mendes, et al.
Diagnostic Microbiology and Infectious Disease|June 19, 2012
LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers)Robert K Flamm, David J Farrell, Rodrigo E Mendes, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 2015
Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancinRonald N Jones, David J Farrell, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease|March 14, 2016
Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitalsHelio S Sader, David J Farrell, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease|September 10, 2016
Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014)Leonard R Duncan, Jennifer I Smart, Robert K Flamm, et al.
International Journal of Antimicrobial Agents|May 29, 2007
Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004)Douglas J Biedenbach, Jan M Bell, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|January 14, 2015
In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanismsRobert K Flamm, Paul R Rhomberg, Katie M Simpson, et al.
The Journal of Antimicrobial Chemotherapy|February 23, 2020
Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwideHelio S Sader, Paul R Rhomberg, Leonard R Duncan, et al.
Jac-Antimicrobial Resistance|October 24, 2025
Antimicrobial susceptibility of Enterobacterales causing infection in the elderly: focus on aztreonam-avibactam and recently approved β-lactamase inhibitor combinationsHelio S Sader, Rodrigo E Mendes, John H Kimbrough, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2014
Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspectiveRichard A Alm, Robert E McLaughlin, Veronica N Kos, et al.
Pageof 42

Showing results (381-390 of 420) with videos related to

Sort By:
Pageof 42
Journal of Chemotherapy (Florence, Italy)|November 24, 2012
ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countriesRobert K Flamm, David J Farrell, Rodrigo E Mendes, et al.
Diagnostic Microbiology and Infectious Disease|June 19, 2012
LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers)Robert K Flamm, David J Farrell, Rodrigo E Mendes, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 2015
Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancinRonald N Jones, David J Farrell, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease|March 14, 2016
Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitalsHelio S Sader, David J Farrell, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease|September 10, 2016
Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014)Leonard R Duncan, Jennifer I Smart, Robert K Flamm, et al.
International Journal of Antimicrobial Agents|May 29, 2007
Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004)Douglas J Biedenbach, Jan M Bell, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|January 14, 2015
In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanismsRobert K Flamm, Paul R Rhomberg, Katie M Simpson, et al.
The Journal of Antimicrobial Chemotherapy|February 23, 2020
Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwideHelio S Sader, Paul R Rhomberg, Leonard R Duncan, et al.
Jac-Antimicrobial Resistance|October 24, 2025
Antimicrobial susceptibility of Enterobacterales causing infection in the elderly: focus on aztreonam-avibactam and recently approved β-lactamase inhibitor combinationsHelio S Sader, Rodrigo E Mendes, John H Kimbrough, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2014
Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspectiveRichard A Alm, Robert E McLaughlin, Veronica N Kos, et al.
Pageof 42